Lexicon Pharmaceuticals (LXRX) Posts Narrower than Expected Q2 Loss of 5c/Sh.
Get Alerts LXRX Hot Sheet
Price: $1.62 -4.14%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
CPSS, HARL, MCET, More
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
CPSS, HARL, MCET, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q2 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $555 thousand versus the consensus estimate of $350 thousand.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rexford Industrial Realty (REXR) Reports In-Line Q1 EPS, provides guidance
- SL Green Realty (SLG) Misses Q1 EPS by 8c, provides guidance
- Discover Financial Services reports mixed Q1 results as earnings fall short
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!